Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
BrightGene Bio-Medical Technology Co Ltd (BrightGene) is a biopharmaceutical company that manufactures, researches and develops preparation drugs, API’s and Intermediates, and veterinary drugs. Its preparation products include dienogest tablets, carboprost tromethamine injection, fondaparinux sodium injection, eribulin mesylate injection, cinacalcet hydrochloride tablets, voriconazole for injection, entecavir tablets, oseltamivir phosphate dry suspension, oseltamivir phosphate capsules, argatroban injection, among others. Its veterinary drugs include seramectin, telavancin hydrochloride, emodes, doramectin and dalbavancin. The company develops products in the therapeutic areas of cardiology, oncology, antibacterial, antifungal and veterinary. BrightGene is headquartered in Suzhou, Jiangsu, China.
Headquarters
China
Address
Building C25-C28, Nano Science Park, No. 218 Xinghu Street, Suzhou Industrial Park, Jiangsu, 215123
Website
www.bright-gene.com
Telephone
86 512 62620988
No of Employees
1,196
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
688166 (SHA)
Revenue (2024)
$170.3M
-4.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-71.2%
(2024 vs 2023)
Market Cap*
$2.2B
Net Profit Margin (2024)
XYZ
-69.8%
(2024 vs 2023)
* As of and is in US$
BrightGene Bio-Medical Technology Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Preparation | Bolining |
| Dienogest Tablets | Youchang |
| Carboprost Tromethamine Injection | Sumilan |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In March, the company secured approval from FDA for Rezafungin. |
| 2022 | Regulatory Approval | In November, Borui Pharmaceuticals (Suzhou) Co., Ltd received the Pimecrolimus notice of rapproval of chemical raw drug marketing application issued by the State Drug Administration. |
| 2022 | Contracts/Agreements | In June, the company and the International Finance Corporation (IFC) of the World Bank Group signed the loan agreement for US$50 million. |
Competitor Comparison
| Key Parameters | BrightGene Bio-Medical Technology Co Ltd | China Pharma Holdings Inc | Ascletis Pharma Inc | Changzhou Sunlight Pharmaceutical Co Ltd | Crystal Pharmatech Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | United States of America |
| City | Suzhou | Haikou | Hangzhou | Changzhou | Cranbury |
| State/Province | Jiangsu | Hainan | Zhejiang | Jiangsu | New Jersey |
| No. of Employees | 1,196 | 215 | 231 | 500 | 300 |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Yuan Jiandong | Chairman; General Manager | Executive Board | 2015 | 55 |
| Ding Nan | Director; Secretary | Executive Board | 2021 | 34 |
| Zou Yuanlai | Director - Financial | Senior Management | 2015 | 54 |
| Li Kai | Deputy General Manager | Senior Management | 2015 | 49 |
| Cheng Zengjiang | Director | Non Executive Board | 2025 | 59 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer